Bristol Myers Squibb Discloses Expiration of RayzeBio Tender Offer; Company Gets Positive CHMP Opinion For Reblozyl (luspatercept) For Treatment of Adults With Transfusion-Dependent Anemia Due To Low-To-Intermediate-Risk Myelodysplastic Syndromes (MDS)
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced the expiration of its tender offer for RayzeBio and received a positive CHMP opinion for Reblozyl (luspatercept) for treating transfusion-dependent anemia in adults with low-to-intermediate-risk Myelodysplastic Syndromes (MDS).
February 23, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's tender offer for RayzeBio has expired, and the company received a positive CHMP opinion for Reblozyl for treating transfusion-dependent anemia in MDS patients.
The expiration of the tender offer for RayzeBio concludes a significant acquisition attempt by BMY, which may have mixed short-term impacts on investor sentiment. However, the positive CHMP opinion for Reblozyl represents a significant regulatory milestone, likely to positively influence BMY's stock in the short term due to the potential for increased sales and market expansion in the treatment of MDS.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100